[
    [
        {
            "time": "2019-08-05",
            "original_text": "The Vanguard Health Care Fund Buys Pfizer, Humana",
            "features": {
                "keywords": [
                    "Vanguard",
                    "Health Care Fund",
                    "Pfizer",
                    "Humana"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-08-05",
            "original_text": "Investors Don’t Like Mylan’s Deal With Pfizer",
            "features": {
                "keywords": [
                    "Investors",
                    "Mylan",
                    "Deal",
                    "Pfizer"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 2,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-08-05",
            "original_text": "The Zacks Analyst Blog Highlights: Caterpillar, Walmart, McDonald's, Pfizer and Marsh & McLennan",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst Blog",
                    "Caterpillar",
                    "Walmart",
                    "McDonald's",
                    "Pfizer",
                    "Marsh & McLennan"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "industrials",
                    "retail",
                    "food service",
                    "healthcare",
                    "insurance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 10,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-08-05",
            "original_text": "52-Week Company Lows",
            "features": {
                "keywords": [
                    "52-Week",
                    "Company Lows"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 2,
                "Importance": 4,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-08-05",
            "original_text": "Health Care Sector Update for 08/05/2019: GLYC, PRVB, ZYME, JNJ, PFE, ABT, MRK, AMGN",
            "features": {
                "keywords": [
                    "Health Care Sector",
                    "GLYC",
                    "PRVB",
                    "ZYME",
                    "JNJ",
                    "PFE",
                    "ABT",
                    "MRK",
                    "AMGN"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-08-05",
            "original_text": "Pfizer Falls 3%",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Falls"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 6,
                "Duration": 2,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-08-05",
            "original_text": "GlycoMimetics stock down 53% after Phase 3 trial failure",
            "features": {
                "keywords": [
                    "GlycoMimetics",
                    "stock",
                    "down",
                    "Phase 3",
                    "trial",
                    "failure"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 1,
                "Importance": 9,
                "Impact": 8,
                "Duration": 1,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-08-05",
            "original_text": "GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails",
            "features": {
                "keywords": [
                    "GlycoMimetics",
                    "Plummets",
                    "Phase 3",
                    "Trial",
                    "Sickle Cell",
                    "Treatment",
                    "Fails"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 1,
                "Importance": 9,
                "Impact": 8,
                "Duration": 1,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]